12:00 AM
 | 
Jun 28, 2012
 |  BC Innovations  |  Strategy

Pharma compounds at the crossroads

The National Center for Advancing Translational Sciences (NCATS) has disclosed details about the first library of therapeutics in its Discovering New Therapeutic Uses for Existing Molecules program (see "Repurposing pharma compounds"). The compounds provided by the program's eight pharma participants have completed at least Phase I testing but did not reach registration for that indication and are available to researchers for experimentation. Although it is not yet clear how researchers will use the library, hints about potential therapeutic avenues can be gleaned from similar compounds in development and from highlights of translational research in the literature. A complete list of library compounds, compound data provided by the participating companies and details about the NIH/NCATS program are available on the agency's National Center for Advancing Translational Sciences, Bethesda, Md.

National Institutes of Health, Bethesda, Md.

Tables

Table 1: Repurposing pharma compounds
Table 1. Repurposing pharma compounds. Source: BCIQ: BioCentury Online Intelligence; National Center for Advancing Translational Sciences (NCATS) website
Company Compound Mechanism Original indication(s)A In commercial developmentB Literature-based indication(s)C
Sanofi (Euronext:SAN; NYSE:SNY) Canosimibe (AVE5530) Sterol O-acyltransferase (SOAT; ACAT) inhibitor Phase III to treat hypercholesterolemia 1 to treat atherosclerosis Alzheimer's disease (AD)
Pfizer Inc. (NYSE:PFE) Senicapoc (PF-05416266; ICA-17043) Potassium channel KCa3.1 (KCNN4) inhibitor Phase IIa to treat asthma, sickle cell disease (SCD) Not available Inflammatory bowel disease (IBD), renal fibrosis
Abbott Laboratories (NYSE:ABT) ABT-639 Calcium channel voltage-dependent T type-α 1H subunit (CACNA1H; Cav3.2) inhibitor Phase II to treat diabetic neuropathic pain (DNP) 1 to treat neuropathic pain Hypertension, obesity
Pfizer Otenabant (CP-945598) Cannabinoid CB1 receptor (CNR1) antagonist Phase III to treat obesity in...

Read the full 1835 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >